Healthcare / BiotechnologyTokyo
$69.00
-1.00 (-1.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-1.0B · quality 37.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-33.5%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-70.4%
FCF CAGR
—
FCF margin
-48874.6%
FCF / Net income
1.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.1M · net income $-1.02B · FCF $-1.03B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.1M | $2.1M | — | $66.0M | $80.9M |
| Net Income | $-1.02B | $-1.02B | $-1.02B | $-1.65B | $-1.68B |
| EBITDA | $-1.05B | $-1.05B | $-1.11B | $-1.79B | $-1.73B |
| EPS | -25.21 | -25.21 | -28.70 | -53.14 | -59.95 |
| Operating Margin | -49861.8% | -49861.8% | — | -2707.4% | -2160.6% |
| Net Margin | -48359.7% | -48359.7% | — | -2505.7% | -2082.3% |
| Balance Sheet | |||||
| Current Ratio | 21.69 | 21.69 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.03B | $-1.03B | $-955.5M | $-1.73B | $-1.51B |
| Returns | |||||
| ROE | -33.5% | -33.5% | -30.2% | -37.7% | -35.9% |
| Valuation | |||||
| P/B | 0.92 | 0.92 | 0.91 | 1.31 | 1.25 |
| Growth & Yield | |||||
| Revenue Growth | — | — | — | -18.5% | — |
| EPS Growth | 12.2% | 12.2% | 46.0% | 11.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-28.70 → -25.21
Residual
-23.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.